-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
!--," August 24, 2020 // --- neutral granulocytes are warriors in the immune system.
they stand ready to take action to help heal damage or fight disease.
unless something goes wrong during their development.
not all of the immature neutral granulocytes are warriors--- they can be dangerous traitors.
high levels of immature neutral granulocytes in the blood can be a sign of cancer and may even be a biomarker of neocyto pneumonia (COVID-19).
, in a new study, researchers from the La Hoya Institute of Immunology (LJI) tracked rare stem cells in human bone marrow that produce neuficial granulocytes.
this provides scientists with a potential way to intervene in diseases in which the development of neutral granulocytes is wrong.
published in the August 18, 2020 issue of the Journal of Immunity under the title "Coexpression of CD71 and CD117 Identifies an Early Unipotent Neutrophil Progenitor Population in Human Bone Marrow."
images from Immunity, 2020, doi:10.1016/j.immuni.2020.07.017.
, a former postdoctoral researcher at the La Hoya Institute of Immunology, said, "We identified stem cells that originated as neuxual granulocytes in the early days.
nucleocytes are the most abundant type of blood cells in humans.
it is particularly interesting to understand how human neutral granulocytes develop, as immature neutral granulocytes have been found in the blood and lungs of patients with severe COVID-19.
" Dinh led the study with Professor Catherine C. Hedrick of the La Hoya Institute of Immunology.
although neutral granulocytes are important, they have proved very difficult to study.
not well preserved in-body, and the stem cells that produce them are harder to study because they only live in bone marrow.
2018, Hedrick Labs reported the discovery of a group of progenitors capable of producing neutral granulocytes (Cell Reports, 2018, doi:10.1016/j.celrep.2018.07.097).
the only job these ancestral cells do is to produce neutral granulocytes, but they also seem to promote tumor growth.
that testing these ancestral cells could give doctors a better way to detect early cancer cases.
first, they need to know more about the development of neutral granulocytes.
new study reveals a type of progenitor cell that exists earlier in human neutrophil development: the very early monopotential bone marrow neutrophil progenitor, eNeP.
Dinh, together with visiting scientist Dr. Tobias Eggert of the La Hoya Institute of Immunology and Dr. Melissa Meyer, a postdoctoral fellow at the La Hoya Institute of Immunology and co-author of the paper, pioneered the use of a tool called flight-time flow cytometry (cytometry by time-of-flight, CyTOF) to distinguish these rare cells from other types of immune ancestral cells.
study also makes it possible to identify more specific protein markers on the surface of these early precellular cells.
found that eNeP cells can be identified by unique surface protein markers CD71 and CD117.
the discovery of these protein markers, because until now, scientists had used only a few markers to track neutral granulocytes.
new study provides scientists with specific markers to track the development of neutral granulocytes from day one.
the researchers also found that cases of skin and lung cancer often come into the bloodstream with immature neutral granulocytes, including these early ancestral cells.
these immature neutral granulocytes change in their interactions with tumor cells, but they are not sure how these changes affect cancer progressity.
Dinh likens the stage of neutral granulocyte development to a train carriage.
early ancestors were like train engines, allowing everything to develop smoothly along the tracks until they matured.
cancer shakes everything, and immature neutral granulocytes jump out of orbit before they reach maturity.
said, "It's like the train's gone."
"Recently, due to the prevalence of COVID-19, the development of neutral granulocytes has been the focus of publicity because studies have shown that in some patients with COVID-19, there are also more immature neutral granulocytes.
Dinh and Hedrick believe that perhaps the threat of SARS-CoV-2 virus is driving the body to produce neutral granulocytes too quickly, and also forcing immature neutral granulocytes out of their mature orbit.
Dingh said, "We need to further study this phenomenon to see if these neutral granulocytes are related to the patient's prognostication, or if they can be targeted for COVID-19 drugs."
the researchers hope to continue their research in order to find the exact mechanisms that prevent neutral granulocytes from maturing.
to understand the ancestral cells that first produced neutral granulocytes is really critical to trying to target and control these cells," he said.
we don't know how that works yet.
" (bioon.com) Reference: 1.Huy Q. Dinh et al. Coexpression of CD71 and CD117 Identifies an Early Unipotent Neutrophil Progenitor Population in Human Bone Marrow. Immunity, 2020, doi:10.1016/j.immuni.2020.07.017.L team get first-ever look at a rare but vital stem cell in humans Peipei Zhu et al. Unity of an Early Unipotent Neutrophil Progenitor with Pro-tumoral Activity in Mouse and Human Bone Marrow. Cell Reports, 2018, doi:10.1016/j.celrep.2018.07.097.4.Researchers find elusive source of most immune cell title . . . . !-- . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .